{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:42:56Z","timestamp":1765370576607,"version":"3.44.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In this review, we explore the role of stereotactic body radiotherapy (SBRT) and other advanced radiotherapy techniques in the treatment of gastrointestinal malignancies, which primarily involves primary and secondary liver cancers and pancreatic cancers. The review examines radiotherapy in both curative and palliative settings, emphasizing the evolution of SBRT and hypofractionation as alternatives to conventional radiotherapy. We review the recent literature evaluating radiotherapy in the management of unresectable, borderline resectable, and metastatic pancreatic cancer, highlighting recent advances in radiotherapy techniques that aim to improve local control, reduce toxicity, and increase resectability in appropriate patients. For primary liver cancers (hepatocellular carcinoma and cholangiocarcinoma), SBRT has emerged as a potential noninvasive alternative to surgery, particularly in patients with unresectable tumors or those awaiting liver transplantation. The review also provides insights into ongoing clinical trials, comparative studies between SBRT and other local therapies such as radiofrequency ablation, and the use of radiotherapy in managing liver metastases from various primary cancers. Throughout, we emphasize limitations in the available literature and highlight areas of ongoing and future investigation.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000752","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:00:30Z","timestamp":1732525230000},"page":"407-420","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A Review of Stereotactic Body Radiotherapy in the Management of Gastrointestinal Malignancies"],"prefix":"10.1097","volume":"30","author":[{"given":"Emily","family":"Hollis","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Nganga","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7123-0637","authenticated-orcid":false,"given":"Ted K.","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250928","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","year":"2021","journal-title":"JAMA"},{"key":"bib2-20250928","first-page":"99","article-title":"Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature","volume":"9","year":"2008","journal-title":"JOP"},{"key":"bib3-20250928","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline","volume":"9","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"bib4-20250928","first-page":"1844","article-title":"Gemcitabine alone or with erlotinib in combination with radiotherapy in patients with locally advanced pancreatic cancer (LAP07)","volume":"315","year":"2016","journal-title":"A multicentre, randomised, phase 2\/3 trial. JAMA"},{"key":"bib6-20250928","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cncr.24059","article-title":"Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas","volume":"115","year":"2009","journal-title":"Cancer"},{"key":"bib7-20250928","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2014.06.066","article-title":"Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity","volume":"90","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib8-20250928","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","year":"2020","journal-title":"Cancer"},{"key":"bib9-20250928","first-page":"100738","article-title":"Stereotactic body radiotherapy for pancreatic cancer\u2014a systematic review of prospective data","volume":"45","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"bib10-20250928","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","year":"2015","journal-title":"Cancer"},{"key":"bib11-20250928","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2021.07.009","article-title":"Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: an open-label, single-arm, phase 2 trial","volume":"162","year":"2021","journal-title":"Radiother Oncol"},{"key":"bib12-20250928","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): long-term outcome","volume":"155","year":"2021","journal-title":"Radiother Oncol"},{"key":"bib13-20250928","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline Resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","year":"2022","journal-title":"JAMA Oncol"},{"key":"bib14-20250928","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1245\/s10434-021-11202-8","article-title":"Neoadjuvant stereotactic body radiotherapy after upfront chemotherapy improves pathologic outcomes compared with chemotherapy alone for patients with borderline resectable or locally advanced pancreatic adenocarcinoma without increasing perioperative toxicity","volume":"29","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"bib15-20250928","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.21.01220","article-title":"Value of neoadjuvant radiation therapy in the management of pancreatic adenocarcinoma","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib16-20250928","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl_2","key":"bib17-20250928","first-page":"1","article-title":"LBA62 - Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS\/PRODIGE 44","volume":"35","year":"2024","journal-title":"Ann Oncol"},{"key":"bib18-20250928","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2022.6138","article-title":"Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX plus radiotherapy in patients with borderline resectable pancreatic cancer\u2014the A021501 trial","volume":"9","year":"2023","journal-title":"JAMA Oncol"},{"key":"bib19-20250928","doi-asserted-by":"crossref","first-page":"20170563","DOI":"10.1259\/bjr.20170563","article-title":"MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer","volume":"91","year":"2018","journal-title":"Br J Radiol"},{"key":"bib20-20250928","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance\u2013guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic Cancer","volume":"117","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib21-20250928","doi-asserted-by":"crossref","first-page":"110064","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study","volume":"191","year":"2024","journal-title":"Radiother Oncol"},{"journal-title":"JCO Oncology Practice","key":"bib22-20250928","article-title":"EXTEND: A randomized, phase II trial of multidisciplinary therapy for metastatic pancreatic cancer"},{"key":"bib23-20250928","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(24)00223-7","article-title":"Stereotactic radiosurgery for the treatment of retroperitoneal pain syndrome in patients with pancreatic and other cancers: An international, multicentre, single-arm, phase 2 trial","volume":"25","year":"2024","journal-title":"The Lancet Oncology"},{"key":"bib24-20250928","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)","volume":"40","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"bib25-20250928","first-page":"357","article-title":"Impact of short-course palliative radiation therapy on pancreatic cancer-related pain: prospective phase 2 nonrandomized PAINPANC trial. International Journal of Radiation Oncology","volume":"118","year":"2024","journal-title":"*\u2022 Biology *\u2022 Physics"},{"key":"bib26-20250928","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00262-024-03744-z","article-title":"Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial","volume":"73","year":"2024","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"bib27-20250928","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: study protocol for a multicenter, open, randomized, phase II-III trial embedded in a nationwide cohort (PANCOSAR)","volume":"22","year":"2022","journal-title":"BMC Cancer"},{"key":"bib28-20250928","article-title":"MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)","volume":"17","year":"2022","journal-title":"Radiation Oncology"},{"key":"bib29-20250928","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/HMER.S278136","article-title":"Challenges and opportunities for treating intrahepatic cholangiocarcinoma","volume":"13","year":"2021","journal-title":"Hepat Med"},{"key":"bib30-20250928","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jjco\/29.3.147","article-title":"Lymph node metastasis in intrahepatic cholangiocarcinoma","volume":"29","year":"1999","journal-title":"Jpn J Clin Oncol"},{"key":"bib31-20250928","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1007\/s00261-023-03991-1","article-title":"Prediction of regional lymph node metastasis in intrahepatic cholangiocarcinoma: it's not all about size","volume":"48","year":"2023","journal-title":"Abdom Radiol (NY)"},{"key":"bib32-20250928","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semradonc.2005.04.005","article-title":"Partial volume tolerance of the liver to radiation","volume":"15","year":"2005","journal-title":"Semin Radiat Oncol"},{"key":"bib33-20250928","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib34-20250928","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","article-title":"Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"bib35-20250928","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2016.07.020","article-title":"Stereotactic body radiotherapy for primary hepatic malignancies \u2013 report of a phase I\/II institutional study","volume":"121","year":"2016","journal-title":"Radiotherapy and Oncology"},{"key":"bib36-20250928","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative radiotherapy doses Lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib37-20250928","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2018.11.015","article-title":"Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma","volume":"132","year":"2019","journal-title":"Radiother Oncol"},{"key":"bib38-20250928","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ctro.2019.07.007","article-title":"Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma","volume":"19","year":"2019","journal-title":"Clinical and Translational Radiation Oncology"},{"key":"bib39-20250928","doi-asserted-by":"crossref","first-page":"20180688","DOI":"10.1259\/bjr.20180688","article-title":"Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review","volume":"92","year":"2019","journal-title":"Br J Radiol"},{"key":"bib40-20250928","first-page":"82","article-title":"Neoadjuvant capecitabine and radiation therapy for patients with hilar cholangiocarcinoma as a bridge to liver transplantation","volume":"20","year":"2014","journal-title":"Liver Transplantation"},{"key":"bib41-20250928","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.3390\/cancers13163991","article-title":"Stereotactic body radiation therapy after chemotherapy for unresectable perihilar cholangiocarcinoma: the STRONG trial, a phase I safety and feasibility study","volume":"13","year":"2021","journal-title":"Cancer"},{"key":"bib42-20250928","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib43-20250928","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1245\/s10434-019-08142-9","article-title":"Hypofractionated radiation therapy for unresectable\/locally recurrent intrahepatic cholangiocarcinoma","volume":"27","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"bib45-20250928","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.21037\/jgo.2020.02.08","article-title":"Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management","volume":"12","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"bib46-20250928","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0360-3016(02)02846-8","article-title":"Analysis of radiation-induced liver disease using the Lyman NTCP model","volume":"53","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib47-20250928","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2023.08.016","article-title":"Defining minimum treatment parameters of ablative radiation therapy in patients with hepatocellular carcinoma: an expert consensus","volume":"14","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"bib48-20250928","first-page":"603","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial","volume":"74","year":"2021"},{"key":"bib49-20250928","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijrobp.2021.03.049","article-title":"A phase 2 study of image-guided proton therapy for operable or ablation-treatable primary hepatocellular carcinoma","volume":"111","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib50-20250928","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/cncr.34965","article-title":"Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: results of a randomized clinical trial","volume":"129","year":"2023","journal-title":"Cancer"},{"key":"bib51-20250928","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.3390\/curroncol29110692","article-title":"Stereotactic radiotherapy after incomplete transarterial (Chemo-) Embolization (TAE\\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: a Phase III Trial (NCT02323360)","volume":"29","year":"2022","journal-title":"Current Oncology"},{"key":"bib52-20250928","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","article-title":"Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY trial)","volume":"117","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib53-20250928","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1200\/JCO.2023.41.4_suppl.489","article-title":"NRG\/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC)","volume":"41","year":"2023","journal-title":"J. Clin. Oncol"},{"key":"bib54-20250928","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/hep.31992","article-title":"Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant","volume":"74","year":"2021","journal-title":"Hepatology"},{"key":"bib55-20250928","first-page":"261","article-title":"Stereotactic body radiotherapy used as a bridge to liver transplant in patients with hepatocellular carcinoma and Child-Pugh score\u2265 8 cirrhosis","volume":"5","year":"2018","journal-title":"J Radiosurg SBRT"},{"key":"bib56-20250928","doi-asserted-by":"crossref","first-page":"55368","DOI":"10.18632\/oncotarget.10552","article-title":"Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib57-20250928","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","article-title":"Stereotactic body radiotherapy (SBRT) for liver metastasis\u2014clinical outcomes from the international multi-institutional RSSearch\u00ae patient registry","volume":"13","year":"2018","journal-title":"Radiat Oncol"},{"key":"bib58-20250928","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.rpor.2016.10.003","article-title":"Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy","volume":"22","year":"2017","journal-title":"Rep Pract Oncol Radiother"},{"key":"bib59-20250928","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-015-0369-9","article-title":"Stereotactic radiation therapy for liver metastases: factors affecting local control and survival","volume":"10","year":"2015","journal-title":"Radiat Oncol"},{"key":"bib60-20250928","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s11547-019-01042-8","article-title":"Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience","volume":"124","year":"2019","journal-title":"Radiol Med"},{"key":"bib61-20250928","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1007\/s12094-020-02375-x","article-title":"Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters","volume":"22","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"bib62-20250928","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ijrobp.2017.12.014","article-title":"Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases","volume":"100","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib63-20250928","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.radonc.2018.06.035","article-title":"Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review","volume":"129","year":"2018","journal-title":"Radiother Oncol"},{"key":"bib64-20250928","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S1470-2045(24)00438-8","article-title":"Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study","volume":"25","year":"2024","journal-title":"Lancet Oncol"},{"key":"bib65-20250928","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib66-20250928","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial","volume":"39","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:00:43Z","timestamp":1759039243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000752","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}